Organoid technology provides researchers with a first-of-its-kind platform for conducting laboratory studies on living diseased tissue, which is impossible to accomplish on patients. It can create human modelling systems in a petri dish, which can be used to develop and test medications before they go through costly clinical trials. Organoid technology stands out as having a major market, with a lot of scientific and business advancements in the fields of stem cells and tissue regeneration. For instance, in August 2021, Stemcell Technologies and Hubrecht Organoid Technology (HUB) announced a collaboration to use tissue-derived organoids, such as intestinal, lung, and liver organoids, in preclinical toxicology screening and non-cancer drug discovery services provided by Stemcell's Contract Assay Services department. These developments in the market will assist drug development specialists and companies in incorporating organoids into their preclinical testing procedures, allowing them to bring new treatments to market efficiently and cost-effectively.
During the forecast period, the market is predicted to rise due to increased spending on healthcare research, as well as other reasons such as the development of the biotech industry. Moreover, the ban on animal testing in various regions and the growing ethical concerns over animal source usage is further expected to contribute to market growth. However, the market's growth will be limited by high initial prices due to the lack of development of organoid technology and rigorous government control a wide range of applications in healthcare. Geographically, the Americas and Europe Middle East and Africa will contribute significantly to the market due to increased government spending and the presence of key industry players.
INCREASING INVESTMENTS IN HEALTHCARE R&D
The organoid technology has gained the significant focus of both government and private players owing to its ability to provide more physiologically relevant and accurate data for the various in-vivo test. They are widely being used in various applications such as disease pathology, tissue morphogenesis, and engineering, gene and protein expression, regenerative medicine, and others. This has resulted in increasing investment in healthcare research & development, especially in the field of Organoid technology, which is likely to be the market's main driver. For example, in 2019, Hubrecht organoid technology (HUB) along with the health insurance companies started a 3-million-pound validation trial for use of this technology to determine the response of Cystic Fibrosis (CF) patients to new drugs therapies. Furthermore, in March 2021, Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that delivers considerable performance and consistency advantages for growing organoids and pluripotent stem cells, was released by Bio-Techne Corporation. UltiMatrix RGF BME fills a gap in the market by providing a consistent, high-concentration cell scaffolding matrix with molecular and physical features tailored to the creation of advanced 2D and 3D cell culture models. Similarly, in March 2019, JSR Corporation partnered with Hubrecht Organoid Technology (HUB) which will allow the former to access HUB’s highly characterized tumour organoid biobank.
Moreover, the increased demand for organoids due to a rising focus on oncological research will also aid market expansion during the forecast period. For instance, in July 2021, Xilis received $70 million in funding to expand its organoid-generation platform for cancer treatment and medication research. Xilis' technique begins by making thousands of additional replicas of a patient's cancer cells to influence the treatment recommendations that will eventually eradicate those cells from the body. Xilis' MicroOrganoSphere technology, or MOS, is at the centre of this technique, which utilizes a tissue sample from a cancer patient to produce miniature models of their tumours.
Additionally, as genomic medicine and gene-edited cell and gene treatments become more common with new technology and specialized expertise, more scientists will be able to conduct individualized therapeutic research and development. As the industry moves toward the industrialization of biology, where automated synthetic biology, cell line generation, and 3D biology research merge, organizations can drive greater capabilities to their consumers by combining organoid technology. For instance, in April 2022, the QPix 400 Series Microbial Colony Picker and the ClonePix 2 Mammalian Colony Picker were added to the Organoid Innovation Center by Molecular Devices, LLC. In addition to automated organoid rearing and screening, this upgrade expands the Center's state-of-the-art technologies and methods to encompass automated processes for synthetic biology, antibody identification, and cell line generation.
CEREBRAL ORGANOID SHOWS PROMISING OPPORTUNITY
Cerebral organoids, also known as neural organoids, are three-dimensional in-vitro culture systems made from human stem cells that mimic the developmental mechanism and structure of the human brain. These in vitro 3D brain models possess a certain feature of a human brain in the first trimester of development that allows the study of neurological development and diseases that are unique to the human nervous system. The increasing prevalence of neurological diseases is generating a surge in the development of cerebral organoids for research purposes. With the rise of an ageing population, the demand for treatment and a better knowledge of such disorders is growing. According to CDC, autism affects about 1.8 per cent of youngsters in the United States, a figure that has more than doubled in the last two decades. Autism is considered to affect one out of every 100 people according to WHO. Schizophrenia affects about 24 million individuals globally according to the Global Health Data Exchange.
Since cerebral organoids are useful for tracking human brain development and neurological illnesses like autism and schizophrenia, as well as brain malformations induced by Zika virus infection, the cerebral organoid technology market is undergoing constant research and development. For instance, in 2019 the researchers at the National Institute of Allergy and Infectious Diseases (NIAID) from the National Institutes of Health (NIH) employed human skin cells to build a cerebral organoid system for researching sporadic Creutzfeldt-Jakob (CJD) disease. The researchers have further developed the organoid system to screen pharmaceuticals for potential CJD treatment in 2021. Further, increasing investment by both public and private players is expected to drive the growth of the segment during the forecast period. For instance, OrganoTherapeutics, a developer of organoids that recapitulate Parkinson's Disease (PD) pathology, entered a partnership with Vyant Bio, Inc., in March 2022 to accelerate the drug discovery for the treatment of Parkinson's Disease. Thus, the ability to provide ethical and more accurate testing results will lead to the growth of the cerebral organoid technology market.
|Growth Rate||CAGR during the forecast period|
|Forecast Unit (Value)||USD Billion|
|Segments covered||Type, Application, End-User, And Geography|
|Regions covered||North America, South America, Europe, Asia Pacific|
|Companies covered||Cellesce Ltd, Organoid Technoligies Gmbh, Hubrecht Organoid Technology, Stemcell Technolgies Inc., 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Inc.|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What is the base year considered in the organoid technology market report?
A1. 2020 has been taken as the base year in the organoid technology market report.
Q2. How is the organoid technology market segmented?
A2. The organoid technology market has been segmented by organ, application, end-user, and geography.
Q3. Who are the major players in the organoid technology market?
A3. Prominent/major key market players in the organoids market include STEMCELL Technologies, Inc., Cellesce Ltd., and Hubrecht Organoid Technology among others.
Q4. What factors are anticipated to drive the organoid technology market growth?
A4. The rise in organoid-led medical research and various discoveries made by them which are beneficial for the treatment of various diseases are contributing significantly to the organoid market growth.
Q5. Which region holds the largest market share in the organoid technology market?
A5. The North American region is anticipated to hold a significant share in the organoid technology market owing to the high healthcare expenditures by governments of countries like the United States and Canada.
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. ORGANOID TECHNOLOGY MARKET ANALYSIS, BY TYPE
5.2. Cerebral Organoid
5.3. Thyroid Organoid
5.4. Thymic Organoid
5.5. Testicular Organoid
5.6. Hepatic Organoid
6. ORGANOID TECHNOLOGY MARKET ANALYSIS, BY APPLICATION
6.2. Cancer Research
6.3. Drug Testing
7. ORGANOID TECHNOLOGY MARKET ANALYSIS, BY END-USER
7.2. Biotechnology and Pharmaceutical Companies
7.3. Academic and Research Institutions
8. ORGANOID TECHNOLOGY MARKET ANALYSIS, BY GEOGRAPHY
8.2.1. United States
8.3. Europe Middle East and Africa
8.3.2. United Kingdom
8.4. Asia Pacific
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Cellesce Ltd
10.2. Organoid Technoligies Gmbh
10.3. Hubrecht Organoid Technology
10.4. Stemcell Technolgies Inc.
10.5. 3Dnamics, Inc.
10.6. Organoid Therapeutics
10.7. PeproTech, Inc.
10.8. Thermo Fisher Scientific
10.9. Corning Inc.
Organoid Technoligies Gmbh
Hubrecht Organoid Technology
Stemcell Technolgies Inc.
Thermo Fisher Scientific
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.